Last close As at 05/08/2026
—
— 0.00 (0.00%)
Market capitalisation
—
Research: Healthcare
Photocure
Written by
Photocure |
Nordic sales bounce back |
Quarterly update |
Pharma & biotech |
25 May 2016 |
Share price performance
Business description
Next events
Analysts
Photocure is a research client of Edison Investment Research Limited |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Photocure announced the second quarter of record sales, NOK33.5m or 18% growth year-on-year and 26% growth in Hexvix/Cysview sales. The growth was on the back of an increase of 20% in unit sales and 23% in revenue from the Nordic region, which marks a return to growth in the region following a slow (5% unit loss) Q415. Sales were further supported by a continued increase in US market share with a 37% increase in unit sales and a 66% increase in revenue.
Year end |
Revenue (NOKm) |
PBT* |
EPS* |
DPS |
P/E |
Yield |
12/14 |
129.0 |
1.5 |
0.07 |
0.0 |
N/A |
N/A |
12/15 |
134.7 |
(17.4) |
(0.82) |
0.0 |
N/A |
N/A |
12/16e |
143.7 |
(11.7) |
(0.54) |
0.0 |
N/A |
N/A |
12/17e |
166.8 |
1.9 |
0.09 |
0.0 |
N/A |
N/A |
Note: *PBT and EPS are normalised, excluding amortisation of acquired intangibles, exceptional items and share-based payments.
Eight more blue light cystoscopy units placed in US
US penetration continues, with eight more blue light cystoscopy units placed in bladder cancer screening facilities during the quarter, bringing the total to 73. Photocure also reported an increased rate of same user sales, bringing the constant currency growth rate to 49%.
Hexvix/Cysview added to bladder cancer guidelines
In April 2016, American Urological Association and the Society of Urological Oncology added the use of blue light cystoscopy and Hexvix/Cysview to their 2016 guidelines for the management of non-muscle invasive bladder cancer. The guidance cited the increased detection and decreased recurrence rate.
Canada and Australia on deck
This quarter marks the first revenue associated with licensing outside of Europe as the company delivered its first units to support the launch of Hexvix/Cysview in Canada with its partner BioSyent. The full commercial launch will begin in Q2/Q316, followed closely behind by approval in Australia by partner Juno Pharmaceuticals, which is expected in Q416.
Valuation: NOK1,591m or NOK74 per basic share
We have increased our valuation to NOK1,591m or NOK74 per basic share (NOK72 per diluted share) from NOK1,499m or NOK70 per basic share (NOK67 per diluted share). The increase is largely due to the inclusion of Canadian, Australian, and New Zealand royalty streams, as well as advancing our NPV. The company ended Q116 with NOK121m in cash. We do not expect the company to need additional financing, but this in part depends on milestones and royalties from Cevira and Visonac, which currently remain unpartnered.
Nordic growth back in full force
Photocure is a pharmaceutical and diagnostic company that has developed a series of photoactive compounds for the detection and treatment of different disorders. The company’s lead product is bladder cancer diagnostic agent hexaminolevulinate hydrochloride (HAL) known in Europe as Hexvix and in North America as Cysview. The compound is metabolized selectively in cancer cells into fluorescent compounds that can be detected using a blue light source (blue light cystoscopy), thereby enabling the improved detection of cancerous lesions in the bladder and a lower rate of recurrence following resection. The company has historically had a strong presence in the Nordic countries where it maintains a 40% market share, but near-term growth is largely driven by expansion into the US. The product is marketed in the rest of the EU through the company’s partner, Ipsen. A Phase III trial is currently ongoing examining Hexvix/Cysview in previously diagnosed patients to screen for additional recurrence or progression of bladder cancer. It is currently only approved for use during surgical procedures. Results from the trial are expected in 2017.
Recently in May 2016, Hexvix/Cysview was added to the guidelines for the management of non-muscle invasive bladder cancer presented by the American Urological Association and the Society of Urological Oncology. The organisations cited both the improved detection rates and the lower rate of recurrence as reason for inclusion.
The company also has two Phase III ready programs utilizing photoactivatable drug/device combinations. Cevira is an insertable light source paired with a photoactivatable gel used for the treatment of cervical dysplasia. It has demonstrated significant efficacy in patients with high-grade squamous intraepithelial lesions. The other product is Visonac, a treatment for inflammatory acne using a face mask and a lamp. Visonac has the potential to treat patients that are resistant to isotretinoin or oral antibiotics. The company is seeking partners to develop both products.
Q116 earnings
Hexvix/Cysview sales remain strong and Q116 marks the second consecutive quarter of record breaking sales (NOK33.5m), albeit on low (1%) sequential growth. Historically, Q4 has been the strongest quarter, so the low sequential growth may be in part due to seasonal effects, although the company has cited a reduced seasonality in the Nordic region during the past twelve months. Total sales revenue growth (including API) year-on-year was 18% for the quarter compared to 34% for Q415.
Exhibit 1: Hexvix/Cysview growth rates year-on-year by region
(%) |
Revenues |
Unit sales |
||
Region |
Q415 |
Q116 |
Q415 |
Q116 |
Nordic |
13 |
23 |
-5 |
20 |
EU |
34 |
14 |
9 |
2 |
US |
95 |
65 |
41 |
37 |
Global in-market |
22 |
19 |
8 |
7 |
Source: Photocure
Sales in the Nordic region grew 23% for the quarter, supported by 20% increase in unit sales, compared to a 5% reduction in unit sales in Q415. This increase, and the corresponding reduction in unit sales for Q415, is largely linked to the reduced seasonality effect described by the company. Sales in this region have been shifting away from Q4 being the strongest toward steady growth. Sweden continues to be the strongest growth market in the region with a 32% increase in unit sales (compared to 17% for Q415).
EU sales reported by the company’s partner Ipsen continue to grow, albeit at a slower rate than expected. Revenue grew 14% for the quarter, but only 4% in constant currency. Unlike previous slow quarters for the region that were caused by inventory drawdowns at Ipsen, this slowing of growth appears to be organic as there was only a 2% increase in end-user unit sales year-on-year.
We expect revenue from partnerships to regain an upward trajectory later in this year due to the upcoming launches in Canada with partner BioSyent and in Australia and New Zealand with Juno Pharmaceuticals. The launch in Canada is planned for Q2/Q316 and approval in Australia is expected in Q416. Q116 revenue represents a small delivery of product to BioSyent in advance of the launch. The company is also evaluating partnerships in Russia.
The US once again proved to be the strongest growth market for Hexvix/Cysview with a 65% increase in revenue. Although unit sales growth decreased slightly from 41% in Q415 to 37% for the current period, revenue on a constant currency basis was up (49% in Q116 compared to 46% in Q415). However, as in previous quarters net currency effects were small with increases in development costs offsetting increased revenue. The net effect of currency for the quarter across the whole company was NOK1.0m. US market expansion was driven by both the increase in sales from existing accounts as well as the placement of new blue light cystoscopes into eight clinics.
Valuation
We have increased our valuation of Photocure to NOK1,591m or NOK74 per basic share (NOK72 per diluted share), from NOK1,499m or NOK70 per basic share (NOK67 per diluted share). The reason for the increase is largely associated with the inclusion of the new Canadian and Australian/New Zealand partnerships and is associated with approximately NOK40m in value. We currently model a 30% royalty in these regions. We predict peak penetration in the 30-33% range before patent expiry because of the favourable reimbursement environments in these countries. Otherwise, besides advancing our NPVs, our model is unchanged.
Exhibit 2: Photocure valuation
Product |
Main Indication |
Status |
Probability of commercialisation |
Launch year |
Peak sales (NOKm) |
Patent protection |
Economics |
rNPV (NOKm) |
Hexvix/Cysview |
Bladder cancer detection |
Market |
100% |
Launched |
387 |
2019-20 |
Fully owned - US and Nordics, Partner with Ipsen in EU (35% royalty), Partner with BioSyent in Canada (30% royalty), Partner with Juno in Aus/NZ (30% royalty) |
690 |
Cevira |
HPV-related diseases |
Phase III |
50% |
2020 |
2,399 |
2030 |
17.5% |
365 |
Visonac |
Acne |
Phase III |
60% |
2020 |
2,175 |
2028 |
17.5% |
415 |
Total |
|
|
|
|
|
|
|
1,470 |
Cash and cash equivalents (Q116) |
121 |
|||||||
Total firm value |
1,591 |
|||||||
Total basic shares (m) |
21.5 |
|||||||
Value per basic share (NOK) |
74 |
|||||||
Options (Q415, m) |
0.8 |
|||||||
Total number of shares (m) |
22.2 |
|||||||
Diluted value per share (NOK) |
72 |
|||||||
Source: Edison Investment Research, company reports
Financials
The company generated NOK34.9m in revenue during Q116 resulting in an EBIT loss of NOK4.9m. The company substantially reduced R&D spending for the quarter (NOK5.6m compared to NOK710m during 2015). SG&A spending was in line with the previous quarter at NOK32.4m. The company reported earnings of NOK1.7m due to a NOK3.6m tax benefit. Cash flows were a negative NOK13.4m largely due to increases in working capital and capex on intangible assets. The company ended the quarter with NOK121m in cash and equivalents, which will be further supplemented by the final payment of €4m from Galderma for the acquisition of Metvix in Q416. We believe that this cash will be sufficient to bring the company to profitability in 2018 following the label expansion of Hexvix/Cysview to bladder cancer screening. We do not expect the company to need additional financing, but the absence of partners for Cevira and Visonac presents a degree of uncertainty regarding development costs and ultimate revenue potential.
Exhibit 3: Financial summary
NOK'000s |
2012 |
2013 |
2014 |
2015 |
2016e |
2017e |
||
Year end 31 December |
IFRS |
IFRS |
IFRS |
IFRS |
IFRS |
IFRS |
||
PROFIT & LOSS |
||||||||
Revenue |
|
|
133,823 |
83,616 |
128,952 |
134,717 |
143,684 |
166,844 |
Cost of Sales |
(9,405) |
0 |
(6,996) |
(8,221) |
(10,831) |
(13,085) |
||
Gross Profit |
124,418 |
83,616 |
121,956 |
126,496 |
132,853 |
153,759 |
||
Sales, General and Administrative Expenses |
(113,583) |
(114,657) |
(95,032) |
(117,136) |
(126,507) |
(132,832) |
||
Research and Development Expense |
(50,083) |
(33,976) |
(32,554) |
(31,337) |
(22,799) |
(23,939) |
||
EBITDA |
|
|
(39,248) |
(71,846) |
(5,630) |
(21,977) |
(16,453) |
(3,012) |
Operating Profit (before GW and except.) |
(39,248) |
(71,846) |
(5,630) |
(21,977) |
(16,453) |
(3,012) |
||
Intangible Amortisation |
0 |
0 |
0 |
0 |
0 |
0 |
||
Other |
0 |
0 |
0 |
0 |
0 |
0 |
||
Exceptionals |
0 |
(3,694) |
0 |
0 |
0 |
0 |
||
Operating Profit |
(39,248) |
(75,540) |
(5,630) |
(21,977) |
(16,453) |
(3,012) |
||
Net Interest |
8,236 |
8,688 |
7,157 |
4,547 |
4,729 |
4,918 |
||
Other |
(11,356) |
(14,015) |
(15,573) |
(9,772) |
0 |
0 |
||
Profit Before Tax (norm) |
|
|
(31,012) |
(63,158) |
1,527 |
(17,430) |
(11,724) |
1,906 |
Profit Before Tax (FRS 3) |
|
|
(42,368) |
(80,867) |
(14,046) |
(27,201) |
(11,724) |
1,906 |
Tax |
890 |
8,204 |
(0) |
0 |
0 |
0 |
||
Deferred tax |
0 |
0 |
(0) |
(0) |
(0) |
(0) |
||
Profit After Tax (norm) |
(30,122) |
(54,954) |
1,527 |
(17,430) |
(11,724) |
1,906 |
||
Profit After Tax (FRS 3) |
(41,478) |
(72,663) |
(14,046) |
(27,201) |
(11,724) |
1,906 |
||
Average Number of Shares Outstanding (m) |
21.3 |
21.2 |
21.3 |
21.4 |
21.6 |
21.8 |
||
EPS - normalised (NOK) |
|
|
(1.42) |
(2.59) |
0.07 |
(0.82) |
(0.54) |
0.09 |
EPS - FRS 3 (NOK) |
|
|
(2.79) |
(3.44) |
(0.66) |
(1.27) |
(0.54) |
0.09 |
Dividend per share (NOK) |
0.0 |
0.0 |
0.0 |
0.0 |
0.0 |
0.0 |
||
BALANCE SHEET |
||||||||
Fixed Assets |
|
|
104,902 |
104,759 |
76,512 |
76,394 |
74,626 |
94,764 |
Intangible Assets |
59,951 |
51,969 |
42,393 |
50,615 |
47,573 |
69,639 |
||
Tangible Assets |
4,111 |
3,681 |
3,056 |
2,288 |
(84) |
(2,012) |
||
Other |
40,840 |
49,109 |
31,063 |
23,490 |
27,137 |
27,137 |
||
Current Assets |
|
|
328,076 |
197,020 |
194,067 |
171,670 |
154,708 |
131,278 |
Stocks |
9,826 |
12,624 |
13,237 |
13,800 |
15,693 |
18,262 |
||
Debtors |
15,432 |
17,085 |
15,585 |
23,844 |
20,928 |
24,355 |
||
Cash |
302,818 |
167,258 |
165,245 |
134,026 |
105,528 |
76,102 |
||
Other |
0 |
53 |
0 |
0 |
12,559 |
12,559 |
||
Current Liabilities |
|
|
(51,089) |
(30,307) |
(27,466) |
(34,039) |
(31,075) |
(31,075) |
Creditors |
(51,089) |
(30,307) |
(27,466) |
(34,039) |
(31,075) |
(31,075) |
||
Short term borrowings |
0 |
0 |
0 |
0 |
0 |
0 |
||
Long Term Liabilities |
|
|
(1,621) |
(2,296) |
(3,055) |
(3,960) |
(4,356) |
(4,792) |
Long term borrowings |
0 |
0 |
0 |
0 |
0 |
0 |
||
Other long term liabilities |
(1,621) |
(2,296) |
(3,055) |
(3,960) |
(4,356) |
(4,792) |
||
Net Assets |
|
|
380,268 |
269,176 |
240,058 |
210,064 |
193,903 |
190,175 |
CASH FLOW |
||||||||
Operating Cash Flow |
|
|
(54,927) |
(99,722) |
(6,089) |
(21,030) |
(219) |
(1,774) |
Net Interest |
0 |
0 |
0 |
0 |
0 |
0 |
||
Tax |
0 |
0 |
0 |
0 |
0 |
0 |
||
Capex |
0 |
0 |
(748) |
(14,930) |
(31,684) |
(30,170) |
||
Acquisitions/disposals |
0 |
0 |
0 |
0 |
0 |
0 |
||
Financing |
0 |
0 |
0 |
0 |
0 |
0 |
||
Dividends |
0 |
0 |
0 |
0 |
0 |
0 |
||
Other |
9,073 |
4,518 |
4,138 |
2,326 |
2,421 |
2,518 |
||
Net Cash Flow |
(45,854) |
(95,204) |
(2,699) |
(33,634) |
(29,482) |
(29,426) |
||
Opening net debt/(cash) |
|
|
(355,173) |
(302,818) |
(167,258) |
(165,245) |
(134,026) |
(105,528) |
HP finance leases initiated |
0 |
0 |
0 |
0 |
0 |
0 |
||
Exchange rate movements |
(1) |
0 |
(1) |
2 |
0 |
0 |
||
Other |
(6,500) |
(40,356) |
687 |
2413 |
984 |
0 |
||
Closing net debt/(cash) |
|
|
(302,818) |
(167,258) |
(165,245) |
(134,026) |
(105,528) |
(76,102) |
Source: Company accounts/Edison Investment Research
|